Strauss Borrelli PLLC, a leading data breach law firm, is investigating Acadia Pharmaceuticals, Inc. (“Acadia”) regarding its recent data breach. The Acadia data breach involved sensitive personal identifiable information and protected health information belonging to an undetermined number of individuals.
ABOUT ACADIA PHARMACEUTICALS, INC.:
Acadia is a pharmaceutical company based in California. Founded in 1993, Acadia has developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome.3 Today, Acadia’s clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders.3 Headquartered in San Diego, California, Acadia employs over 500 individuals.
WHAT HAPPENED?
Recently, Acadia was informed that its business partner, Cencora, Inc., and its Lash Group affiliate had experienced a data breach in which sensitive protected health information belonging to Acadia customers in its systems may have been accessed and acquired. Through its investigation, Cencora determined that an unauthorized actor gained access to this sensitive information on February 21, 2024. On May 20, 2024, Cencora began notifying individuals whose information may have been impacted. The type of information potentially exposed includes:
- Name
- Date of birth
- Address
- Medical information (e.g., health diagnosis, and/or medications and prescriptions)
If you received a breach notification letter from Acadia Pharmaceuticals, Inc., Cencora, Inc., or The Lash Group:
We would like to speak with you about your rights and potential legal remedies in response to this data breach. Please fill out the form, below, or contact us at 872.263.1100 or sam@straussborrelli.com.
